Form 4: AEON Biopharma Director Jost Fischer Reports Stock and Option Awards
SEC Form 4 Filing
Director Jost Fischer reports acquisition of stock and option awards in AEON Biopharma, Inc.
Summary
- Jost Fischer, a director of AEON Biopharma, Inc., reported changes in beneficial ownership.
- On August 31, 2024, Fischer acquired 36,021 shares of Class A Common Stock through a restricted stock unit (RSU) award that vests on the second anniversary of the grant date.
- Fischer also acquired 96,210 stock options with an exercise price of $0.83, vesting monthly over 18 months following the grant date of August 31, 2024, and expiring on August 30, 2034.
- The report also corrects a previous error, reclassifying 19,286, 6,289, and 35,189 RSUs previously reported as derivative securities as common stock.
Sentiment
Score: 7
Explanation: The sentiment is neutral to positive. The granting of equity to a director is generally viewed favorably as it aligns interests with shareholders. The correction of a previous reporting error is also a positive sign of attention to detail.
Positives
- The grant of stock options and restricted stock units to a director aligns their interests with those of the shareholders.
- The vesting schedules for the RSUs and stock options incentivize continued service and commitment to the company.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, which is crucial for investor confidence.
Comparison to Industry Standards
- Stock option and RSU grants are common compensation practices for directors in publicly traded biopharmaceutical companies.
- Vesting schedules, such as the 18-month monthly vesting for the options and the two-year vesting for the RSUs, are typical for aligning director incentives with long-term company performance.
- Similar companies such as Revance Therapeutics and Evolus also utilize stock options and RSUs as part of their director compensation packages.
Stakeholder Impact
- Shareholders may view the equity grants positively as they align the director's interests with the company's long-term success.
- Employees may see the grants as a sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 04/26/2023 | Date of previously granted RSUs (19,286, 6,289, and 35,189). |
| 07/24/2023 | Date of previous report where RSUs were incorrectly reported as derivative securities. |
| 08/31/2024 | Date of the reported transaction: grant of RSUs and stock options. |
| 08/30/2034 | Expiration date of the stock options. |
| 09/04/2024 | Date of the Form 4 filing. |
Keywords
AEON Biopharma, Director, Form 4, Stock Options, Restricted Stock Units, Beneficial Ownership, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.